XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
COGT Cogent Biosciences
- 8.030
- -0.150-1.83%
Close Feb 14 16:00 ET
- 8.090
- +0.060+0.75%
Post 20:01 ET
887.01MMarket Cap-3.24P/E (TTM)
8.370High7.980Low841.41KVolume8.240Open8.180Pre Close6.76MTurnover1.31%Turnover RatioLossP/E (Static)110.46MShares12.61052wk High4.35P/B515.21MFloat Cap5.73052wk Low--Dividend TTM64.16MShs Float174.200Historical High--Div YieldTTM4.77%Amplitude1.904Historical Low8.039Avg Price1Lot Size
Cogent Biosciences Stock Forum
Sign in to post a comment
$Cogent Biosciences (COGT.US)$
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...
1
$Cogent Biosciences (COGT.US)$
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...
1
$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces Positive Updated Data From Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients With Advanced Systemic Mastocytosis (AdvSM)
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...
1
$Cogent Biosciences (COGT.US)$ Reuters· 3 mins ago
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
$Cogent Biosciences (COGT.US)$ Cogent Biosciences (COGT) said Thursday that new lead-in data from ongoing phase 3 trial of a combination of bezuclastinib and sunitinib showed potential to become new standard of care for advanced gastrointestinal stromal tumors, a type of cancer.
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
1
5
$Cogent Biosciences (COGT.US)$ Cogent Biosciences Reports Updated Lead-In Data From Ongoing Phase 3 PEAK Trial At ASCO Annual Meeting
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
1
Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
$Cogent Biosciences (COGT.US)$ Cogent Biosciences Announces Positive Part 1b Data From SUMMIT Trial Evaluating Bezuclastinib in Patients With Nonadvanced Systemic Mastocytosis
GlobeNewswire· 30 mins ago
GlobeNewswire· 30 mins ago
$Cogent Biosciences (COGT.US)$ new data is comin for mastocytosis, the presentation is scheduled at AAAAI conference in a couple of days. And bezuclastinib soon will be a new standard of care for GIST.
No comment yet
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Peasant Investor OP : Shit this was a wrong trade, whale exited initial position